clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fujimura S et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. 2015 J. Infect. Chemother. pmid:26162777
Cavkaytar S et al. Clarithromycin regresses endometriotic implants in rat endometriosis model. 2015 J Obstet Gynaecol pmid:26156575
Bai P et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. 2015 J Dig Dis pmid:26147515
Nie W et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. 2015 Biomed Res Int pmid:26146620
Kozan G et al. Effect of systemic clarithromycin and prednisolone on histamine-induced otitis media in guinea pigs. 2015 Acta Otolaryngol. pmid:26143935
Ferro BE et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. 2015 J. Antimicrob. Chemother. pmid:26142475
Honda M et al. Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial. 2015 J. Am. Coll. Surg. pmid:26141464
Matsumoto T et al. Mycobacterium fortuitum thoracic empyema: A case report and review of the literature. 2015 J. Infect. Chemother. pmid:26139179
Losurdo G et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'. 2015 Int. J. Clin. Pract. pmid:26138290
Reveiz L and Cardona AF Antibiotics for acute laryngitis in adults. 2015 Cochrane Database Syst Rev pmid:26002823
Ahmed S and Atia NN Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. 2015 Spectrochim Acta A Mol Biomol Spectrosc pmid:25459696
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Rose SJ et al. Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. 2015 PLoS ONE pmid:26010725
Srivastava AK et al. In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. 2015 Arch. Pharm. (Weinheim) pmid:25996140
Koh WJ et al. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. 2015 Antimicrob. Agents Chemother. pmid:25987622
Tsunemine H et al. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. 2015 Gan To Kagaku Ryoho pmid:25981655
Zhang S et al. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. 2015 Cancer Lett. pmid:25853150
Zhang S and Long C Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. 2015 J. Pediatr. Hematol. Oncol. pmid:25851555
Burton AJ et al. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. 2015 Antimicrob. Agents Chemother. pmid:25824218
Kazama I et al. Macroscopic haemoglobinuria associated with Mycoplasma pneumoniae infection successfully treated by clarithromycin. 2015 Infez Med pmid:25819056
Silva JT et al. Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review. 2015 Transpl Infect Dis pmid:25816889
Sugawara M et al. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan. 2015 J. Dermatol. pmid:25809502
Andrianov M et al. A 15-year-old boy with abdominal pain, growth retardation, and anemia secondary to Helicobacter pylori-associated peptic ulcer. 2015 Pediatr Ann pmid:25806733
Zhao C et al. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012]. 2015 Zhonghua Jie He He Hu Xi Za Zhi pmid:25791651
Kimko H et al. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen. 2015 J Clin Pharmacol pmid:25639255
Berry AC et al. Not All Helicobacter Are pylori. 2015 Clin. Gastroenterol. Hepatol. pmid:25638590
Dinca EB et al. The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:25629665
Liu Q et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection. 2015 Eur J Gastroenterol Hepatol pmid:25629566
Genc G et al. Does systemic clarithromycin therapy have an inhibitory effect on tympanosclerosis? An experimental animal study. 2015 J Laryngol Otol pmid:25619629
Winkel P et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. 2015 Int. J. Cardiol. pmid:25602299
Trespalacios AA et al. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. 2015 Diagn. Microbiol. Infect. Dis. pmid:25600075
Galvidis I et al. Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes. 2015 Anal. Biochem. pmid:25256165
Siekmeier R et al. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. 2015 Adv. Exp. Med. Biol. pmid:25252902
Kim H et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 Ann. Hematol. pmid:25501820
Phan TN et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. 2015 Int. J. Antimicrob. Agents pmid:25499186
Adebisi AO et al. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. 2015 J. Pharm. Pharmacol. pmid:25496042
Tsay FW et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. 2015 Helicobacter pmid:25495272
Mourad-Baars PE et al. Low antibiotic resistance of Helicobacter pylori in The Netherlands. 2015 Helicobacter pmid:25495199
Frija-Masson J et al. [Non-tuberculous mycobacterial infection of a totally implanted perfusion device]. 2015 Rev Mal Respir pmid:25480387
Lee H et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. 2015 Dig Liver Dis pmid:25467826
Dierig A et al. Antibiotic treatment of pertussis: are 7 days really sufficient? 2015 Pediatr. Infect. Dis. J. pmid:25247586
Zhang Y et al. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. 2015 Carcinogenesis pmid:26449252
Mailleux M et al. Unusual pulmonary toxicity of ipilimumab treated by macrolides. 2015 Acta Clin Belg pmid:26790556
Jesus FP et al. In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. 2015 Antimicrob. Agents Chemother. pmid:26459895
Higuchi K et al. Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study. 2015 Gastric Cancer pmid:25098924
Basyigit S et al. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. 2015 Bosn J Basic Med Sci pmid:26614852
Shin SH et al. Helicobacter pylori Eradication Prevents Metachronous Gastric Neoplasms after Endoscopic Resection of Gastric Dysplasia. 2015 PLoS ONE pmid:26580072
Desai S et al. The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013. 2015 PLoS ONE pmid:26569613
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Nishizawa T et al. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. 2015 J. Clin. Gastroenterol. pmid:24921211
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Boyanova L et al. Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. 2015 Int. J. Antimicrob. Agents pmid:26453146
Rubio M et al. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. 2015 PLoS ONE pmid:26448181
Barni S et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. 2015 J Investig Allergol Clin Immunol pmid:25997306
Vliegenthart AD et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. 2015 Sci Rep pmid:26489516
Fasciana T et al. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. 2015 J. Med. Microbiol. pmid:26338221
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Zhu YC et al. Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus. 2015 Mol. Cell. Probes pmid:26334290
Georgopoulos SD et al. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. 2015 Expert Opin Pharmacother pmid:26330278
Koide T et al. Analysis of Distribution of Ingredients in Commercially Available Clarithromycin Tablets Using Near-Infrared Chemical Imaging with Principal Component Analysis and Partial Least Squares. 2015 Chem. Pharm. Bull. pmid:26329859
Nozawa K et al. Effect of surfactants or a water soluble polymer on the crystal transition of clarithromycin during a wet granulation process. 2015 Int J Pharm pmid:26325306
Renvoisé A et al. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 2015 Antimicrob. Agents Chemother. pmid:26324275
Dingemanse C et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. 2015 Carcinogenesis pmid:26320104
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Sancak S et al. Intestinal blood flow by Doppler ultrasound: the impact of clarithromycin treatment for feeding intolerance in preterm neonates. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26135789
Uehara H et al. Comparison of the Anti-angiogenic and Anti-inflammatory Effects of Two Antibiotics: Clarithromycin Versus Moxifloxacin. 2016 Curr. Eye Res. pmid:26125497
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Khashei R et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. 2016 APMIS pmid:27357065
Alarcón-Millán J et al. Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis. 2016 Infect. Genet. Evol. pmid:27355861
Khonche A et al. Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial. 2016 Drug Res (Stuttg) pmid:27351245
Büchsel M et al. A case of septic arthritis caused by a Mycoplasma salivarium strain resistant towards Ciprofloxacin and Clarithromycin in a patient with chronic lymphatic leukemia. 2016 Diagn. Microbiol. Infect. Dis. pmid:27342785
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Mayor S Short term increase in neuropsychiatric events is seen with H pylori treatment containing clarithromycin. 2016 BMJ pmid:27143325
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Wong AY et al. Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin. 2016 JAMA Intern Med pmid:27136661
Zollner-Schwetz I et al. Primary resistance of Helicobacter pylori is still low in Southern Austria. 2016 Int. J. Med. Microbiol. pmid:27134190
Georgopoulos SD et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. 2016 Eur. J. Intern. Med. pmid:27134145
Todo K et al. Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female. 2016 Ann. Hematol. pmid:26957356
Iyer G and Alexander GC Editorialists' reply to Blake. 2016 BMJ pmid:26957321
Blake Z Study provides insufficient evidence of a link between clarithromycin and myocardial infarction. 2016 BMJ pmid:26955978
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Ji Z et al. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. 2016 Medicine (Baltimore) pmid:26937912
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Raymond J et al. Diagnosis of Helicobacter pylori recurrence: relapse or reinfection? Usefulness of molecular tools. 2016 Scand. J. Gastroenterol. pmid:26784882
Kefeli A et al. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. 2016 Bosn J Basic Med Sci pmid:26773183
Iyer G and Alexander GC Cardiovascular risks associated with clarithromycin. 2016 BMJ pmid:26769796
Wong AY et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. 2016 BMJ pmid:26768836
Jain SK et al. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. 2016 AAPS PharmSciTech pmid:26566630
Di Giulio M et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. 2016 Scand. J. Gastroenterol. pmid:26554617
Djennane-Hadibi F et al. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. 2016 Microb. Drug Resist. pmid:26554340
Gehlot V et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. 2016 J Glob Antimicrob Resist pmid:27530837
Xuan SH et al. Detection of clarithromycin-resistant Helicobacter pylori in clinical specimens by molecular methods: A review. 2016 J Glob Antimicrob Resist pmid:27436390
Siddiqui TR et al. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. 2016 J Pak Med Assoc pmid:27339574
Lee J et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26441216
Shimizu T and Suzaki H Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. 2016 Auris Nasus Larynx pmid:26441370
Apostolopoulos P et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. 2016 Scand. J. Gastroenterol. pmid:26435055